Trial Profile
A phase 2 randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of MBX-102 in combination with allopurinol in gout patients with an inadequate hypouricemic response to allopurinol alone
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Arhalofenate (Primary) ; Allopurinol
- Indications Gout
- Focus Therapeutic Use
- Sponsors CymaBay Therapeutics
- 01 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 Jul 2011 New trial record